Senores Pharmaceuticals Limited IPO
Senores Pharmaceuticals Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹372–₹391 per share to raise ₹82 crore. The issue was subscribed 93.69× overall (QIBs 94.66×, NIIs 96.3×, retail 90.46×). It listed on 30 Dec 2024 at ₹600 and closed its first day at ₹557, a listing gain of +42.5% versus the ₹391 issue price. It now trades around ₹1,134 (+190.0% versus the issue price).
Frequently asked questions
- How many times was the Senores Pharmaceuticals Limited IPO subscribed?
- The Senores Pharmaceuticals Limited IPO was subscribed 93.69× overall — 94.66× in the QIB category, 96.3× among non-institutional investors, 90.46× in retail.
- What were the Senores Pharmaceuticals Limited IPO listing gains?
- Senores Pharmaceuticals Limited listed on 30 Dec 2024 at ₹600, closing its first day at ₹557 — a listing gain of +42.5% versus the ₹391 issue price.
- What were the retail allotment odds for the Senores Pharmaceuticals Limited IPO?
- Retail was subscribed 90.46×, so a single-lot application had roughly a 1.1% chance of allotment (about 1 in 90), and allotment was finalised on 26 Dec 2024.
- What was the price band and lot size of the Senores Pharmaceuticals Limited IPO?
- The price band was ₹372–₹391 per share, with a minimum lot of 38 shares (₹14,858 at the upper band).
- Who were the registrar and lead manager for the Senores Pharmaceuticals Limited IPO?
- Link Intime India Private Limited was the registrar, and Equirus was the book-running lead manager.